Documents transmis le 16/03/2021 - Latanoprost

PUBLIÉ LE 20/05/2021 - MIS À JOUR LE 29/05/2026

- AMM Vizilatan 50 microgrammes/ml, collyre en solution (2018)
- Latanoprost - Braille (2018)
- Latanoprost - Annexe 54 (2017)
- Latanoprost - Manufacturer's authorisation (2017)
- Latanoprost - Certificate of GMP compliance of a manufacturer
- Latanoprost - Letter of access (2017)
- Latanoprost - Letter of commitment (2017)
- Latanoprost - Annexe 517 (2017)
- Latanoprost - List of proposed (invented) names and marketing authorisation holders in the concerned member states (2017)
- Latanoprost - Certificate of GMP compliance of a manufacturer
- Latanoprost - Submission of Application Dossier(s) for Marketing Authorisation of Latanoprost 50 micrograms/mL PF eye drops solution (2017)
- Latanoprost - Package leaflet: Information for the user (2017)
- Latanoprost - Justification for Absence of Environmental Risk Assessment (2017)
- Latanoprost - Product information (2017)

Latanoprost - Labelling (2017)

Latanoprost - Exclu (2017)

Latanoprost - Information for generic, “hybrid” or bio-similar applications (2017)

Latanoprost - Notice to applicants (2015)

Latanoprost - Patent (2017)

Latanoprost - Risk management plan (2017)

Latanoprost - Summary of the Valeant group Pharmacovigilance System (2017)

Latanoprost - Summary of product characteristics (2017)

Latanoprost - Extrait Kbis (2017)

Latanoprost - Specimen (2017)

Latanoprost - Track (2017)

Latanoprost - Appendices (2017)

Latanoprost - Clinical overview (2017)

Latanoprost - Introduction (2017)

Latanoprost - Nonclinical summary (2017)

Latanoprost - Nonclinical overview (2017)

Latanoprost - Clinical summary (2017)

Latanoprost - Regional information / For EU (2017)